• linkedin
  • Increase Font
  • Sharebar

    Companies acquire rights to low T, IC drugs

    In separate actions, two pharmaceutical makers have acquired the rights to a novel testosterone agent and a patented formulation for interstitial cystitis/painful bladder syndrome (IC/PBS).

    Endo International plc announced acquisition rights to testosterone nasal gel (Natesto) from Trimel BioPharma SRL. The drug was approved by the FDA in May 2014.

    RELATED: Group calls for investigation of JAMA over T study

    Endo said it expects the transaction to close in early 2015. 

    "We are pleased to acquire the rights to Natesto to further enhance our branded pharmaceutical portfolio and look forward to leveraging our commercial expertise in the areas of men's health and urology to support this highly differentiated product," Rajiv De Silva, president and CEO of Endo, said in a news release.

    Natesto offers a unique intranasal delivery system. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

     

    Next: License agreement announced for IC/BPS treatment

    You might also like:

    Data fail to support concerns over T therapy, CV risk

    Men too often receive T for ‘soft’ indications

    FDA OKs low T nasal gel, male incontinence device

    AUA IC/BPS guideline update highlights new data

    Genomic variation in IC/BPS based on bladder capacity
     

    Richard R. Kerr
    Kerr is group content director for Urology Times.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results